CEO / CSO / Board Chair
Dr. Daryl Lawson
PT, DSc. Founder-scientist. Professor and director of the University of Nevada, Reno Doctor of Physical Therapy program. The published heat and stimulation series is his research line.
Investors
An underserved problem. A 15-year research line. A team built to finish the device.
Diabetic foot ulcers cost the U.S. healthcare system roughly $11 billion a year, yet treatment has not meaningfully changed in a generation. SenLore is built on a research line from co-founder Dr. Daryl Lawson, producing 9 peer-reviewed papers, 3 national poster presentations, and 4 granted U.S. patents — before Adlore became a company.
Hospital and published ES + heat studies; not an FDA-cleared claim.
Why this team
Engineering advisor
Chris Arena, PhD
Virginia Tech Biomedical Engineering. Collaboration with Dr. Lawson dates to Elon University (2017), not only the current Virginia Tech role. Prototype, experimental learning, and device engineering counsel.
Why cheaper to finish than a typical device company
CEO and CSO Dr. Lawson is a professor at an R1 university (UNR DPT) — access to IRB review, students, labs, and non-dilutive funding paths (NIH, DoD/MTEC, state biotech, VA rural and limb-preservation mechanisms) that a typical device startup has to buy with equity.
Two intended revenue streams
Category-level reimbursement design — not a projection of revenue, and not an offer of securities. SenLore is investigational and not for sale.
Durable medical equipment
Off-loading boot pathway
Designed to ride existing off-loading-boot and diabetic-insert codes clinicians already use — a one-time or replacement-cycle stream, not a new care pathway.
Remote therapeutic monitoring
Monthly clinical review
Setup, device data, and timed clinical-review codes for home monitoring — the billing category a detection-only product typically cannot access. Category description, not a named-competitor comparison.
Development plan
An 11-month plan from company materials: lock the prototype, file a 510(k) package, and start VA and rural pilots. This is a development roadmap, not a forecast of clearance or commercial availability.
Months 0–3
Prototype completion
Electrode array, sensors, enclosure, firmware, and the remote-monitoring data hook.
Months 3–6
Bench and safety testing
Electrical safety and EMC, human factors, cybersecurity documentation, and design freeze.
Months 6–9
510(k) package
Predicate confirmed with counsel, test reports assembled, submission filed. SenLore is not FDA-cleared today.
Months 9–11
First sites
Open a VA coordinator path, start one rural hospital site, and stand up a quality-system skeleton.
Where things stand
SenLore is in active development. It is investigational, not FDA-cleared, and not for sale. Adlore's next steps are a locked prototype, a 510(k) submission package, and first pilot sites with VA and rural partners. Investment terms and offering details appear with Highlander and Strong Capital Markets.
Campaign status
Offering channels
Whether a Regulation Crowdfunding offering is open, and any progress toward a target, is published only on Highlander. Regulation D terms, if discussed, are handled through Strong Capital Markets — not as a percentage on this site.
Follow our progress
Get development updates
A low-commitment way to follow prototype, clearance-path, and news updates. Not an investment, and not a request for health information.
Development
Prototype, not clearance
SenLore remains investigational. Prototype photography on this site is the current hardware, not a finished commercial product.
For investors
Adlore is raising through two separate channels. A Regulation Crowdfunding (Reg CF) offering, when open, is available only on Highlander — that is the public campaign and the only place to see those terms, eligibility, and how to invest. Separately, Adlore is working with Strong Capital Markets on a Regulation D private placement for accredited investors. If you are accredited and want to discuss that raise, use the contact form or reach Strong Capital Markets directly. Do not send health information or patient details through this site. SenLore is an investigational device, not FDA-cleared, and not for sale; an investment is in Adlore, Inc., not a purchase of the boot.
Information on this website is not an offer to sell securities or a solicitation of an offer to buy securities.
Questions we hear often
Is SenLore™ FDA-cleared?
No. SenLore is an investigational device. It is not cleared or approved by the FDA and is not available for sale.
Is this safe?
This website does not claim that SenLore is safe or effective. The device has not been cleared or approved by the FDA. Always consult a qualified clinician about diabetic foot ulcers. Foundational studies of heat and electrical stimulation are not a substitute for evaluation of a commercial SenLore product.
Why isn’t it for sale yet?
SenLore is still in prototype development. Adlore’s next steps are a locked prototype, a 510(k) submission package, and first pilot sites. It is investigational and not for sale.
When can I get one?
There is no commercial availability date on this site. Photos show a prototype in development. Follow News or the progress list for development updates — those are not a waitlist for a cleared product.
Can patients buy or use SenLore today?
Not as a commercial product. The photos on this site show a prototype in development.
What is SenLore designed to do?
It is being developed as a wearable boot that combines controlled heat and electrical pulse stimulation, with sensors intended to support remote monitoring of diabetic foot ulcers. That is a design intent, not a claim that the commercial device has been proven to heal wounds.
How is the boot designed to work?
Heat and electrical stimulation are intended to prompt endothelial cells to release nitric oxide, supporting vasodilation and increased circulation in the foot. Foundational studies of that combination are not the same as clinical results for a finished SenLore product.
Are the statistics on this site results from SenLore?
No. Published numbers come from hospital and published ES + heat studies, including work Dr. Lawson began in his doctoral research. They are comparable to that clinical series — not FDA-cleared claims about a finished SenLore product.
How can I invest?
Adlore is raising through two separate channels. A Regulation Crowdfunding offering, when open, is available only on Highlander. Accredited investors can discuss a separate Regulation D placement with Strong Capital Markets. Terms for either offering are not published in story copy on this site.
What happens to my money if I invest?
Investment terms, eligibility, and how funds are handled appear only in the official offering materials — on Highlander for Regulation Crowdfunding, or through Strong Capital Markets for the Regulation D placement. This website is not an offer to sell securities and does not publish raise amounts or use of proceeds.
SenLore™ is an investigational device, not yet available for sale or cleared by the FDA.